ArticleSichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition2025
[Risk Factors and Etiology of Pulmonary Fungal Infection in Patients With End-Stage Liver Disease].
Article in Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To identify the risk factors and investigate etiological spectrum of pulmonary fungal infections (PFIs) in patients with end-stage liver disease (ESLD). Methods: A retrospective analysis was performed on the clinical data of 211 ESLD patients. Based on pulmonary imaging, clinical manifestations, and microbiological test results, patients were categorized into three groups, including the PFI group (or the case group), the non-fungal pneumonia group (or the control group 1), and the group without pneumonia (or the control group 2). The clinical characteristics of patients in the the case group were then compared with those of patients in the two control groups. Taking patients without pneumonia as the control, univariate and multivariate logistic regression analyses were performed to identify independent risk factors for PFI, and a nomogram prediction model was constructed based on these risk factors. Results: Among the 211 patients, 76 (36.1%) had PFIs, 46 (21.8%) had non-fungal pneumonia, and 89 (42.2%) did not have pneumonia. According to findings from the multivariate logistic regression, elevated white blood cell count upon admission (OR = 1.211; 95% CI, 1.011-1.460), higher Model for End-Stage Liver Disease-Sodium (MELD-Na) score (OR = 1.140; 95% CI, 1.021-1.282), concomitant hepatorenal syndrome (OR = 4.150; 95% CI, 1.050-17.300), cumulative glucocorticoid use for more than seven days (OR = 26.832; 95% CI, 6.361-113.221), and the administration of broad-spectrum antibiotics at the time of hospital admission (OR = 6.601; 95% CI, 1.951-22.362) were identified as independent risk factors for PFI. A predictive nomogram model named TJLFPFI was constructed based on these risk factors. The area under the receiver operating characteristic (AUC) curve of the model was 0.899 (95% CI, 0.853-0.945). Etiologic analysis of the 76 PFI cases revealed that 36 (47.4%) had positive results for culture, while 40 (52.6%) had negative results for sputum culture but tested positive by the 1,3-β-D-glucan test and/or galactomannan test. Aspergillus was the most frequently identified pathogen, detected in 25 of the 36 cases (59.5%). Conclusion: PFI in ESLD patients is closely associated with disease severity at admission, early use of broad-spectrum antibiotics, and prolonged glucocorticoid therapy. Aspergillus is the predominant pathogen. The TJLFPFI model shows potential value in identifying high-risk patients, but prospective validation is still warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.